Answers are grounded in this paper and cite their sources.
Computational design reveals enzymatic activity in artificial metallopeptides, suggesting new organometallic uses.
Artificial metallopeptides hold immense potential to combine enzymatic activity with the versatility of organometallic catalysts. However, computational de novo design is largely limited to theozyme models that may neglect second-sphere...
No takes yet. Share an insight, caveat, or question.
Domnin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: